prostate cancer

[Cellular & Molecular Biology Letters] SNHG3 as a molecular sponge of miR-152-3p stimulated proliferation, migration, and invasion, restrained methionine dependence and apoptosis, and affected the cell cycle of prostate cancer (PCa) cells via targeting SLC7A11.

[British Journal of Radiology] Scientists summarize the potential and current evidence for MRI-guided radiotherapy, with a predominant focus on prostate cancer.

[LAVA Therapeutics] LAVA Therapeutics announced dosing of the first patient in the company’s Phase I/IIa clinical trial of LAVA-1207 in patients with metastatic CRPC.

[Ultimovacs] Ultimovacs announced it has completed treatment of the second dose cohort in the Phase I TENDU trial. The study is designed to evaluate the company's tetanus-epitope targeting-platform in patients with prostate cancer.

[Molecular Cancer Research] Researchers found that combining p110β with RAC/PAK1 or tankyrase inhibitors significantly reduced the growth of murine and human CRPC organoids in vitro and in vivo.

[Nature Communications] Scientists showed RIPK2 was a clinically actionable target for inhibiting prostate cancer (PC) metastasis. RIPK2 was amplified/gained in ~65% of lethal metastatic castration-resistant PC.